# Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

> **NCT06343779** · PHASE3 · COMPLETED · sponsor: **Pharvaris Netherlands B.V.** · enrollment: 134 (actual)

## Conditions studied

- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor [C1-INH] Deficiency
- C1 Esterase Inhibitor Deficiency
- C1 Esterase Inhibitor, Deficiency of
- C1 Inhibitor Deficiency
- Hereditary Angioedema - Type 3
- Hereditary Angioedema Type III

## Interventions

- **DRUG:** Deucrictibant, Placebo

## Key facts

- **NCT ID:** NCT06343779
- **Lead sponsor:** Pharvaris Netherlands B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-26
- **Primary completion:** 2025-10-17
- **Final completion:** 2025-10-17
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343779, "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06343779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*